Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback